Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era

Conclusion We conclude that outcomes for FL grade 3, primarily treated with R-CHOP, do not differ between FL3A and aggFL (FL3B and FL3/DLBCL). The aggFL group showed a plateau in PFS confirming these should be treated with curative intent. FL3A patients, mainly managed with R-CHOP, also show an apparent plateau in PFS. While longer follow-up and confirmation in other datasets is required, this indicates potential under-treatment of FL3A with less aggressive regimens often used for indolent lymphoma. Teaser Whether to clinically approach follicular lymphoma (FL) grade 3 as an indolent or aggressive lymphoma, especially since the introduction of rituximab, is unclear. Our experience with FL grade 3A, compared with FL grade 3B or with concomitant diffuse large B cell lymphoma, primarily treated with R-CHOP suggests possible long-term remissions. This must be confirmed with longer follow-up and additional studies.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research